Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,199 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
One-month relative dose intensity of not less than 50% predicts favourable progression-free survival in sorafenib therapy for advanced renal cell carcinoma in Japanese patients.
Kawashima A, Takayama H, Arai Y, Tanigawa G, Nin M, Kajikawa J, Imazu T, Kinoshita T, Yasunaga Y, Inoue H, Nishimura K, Takada S, Nishimura K, Tsujimura A, Nonomura N; Osaka Renal Cell Carcinoma Clinical Study Collaboration. Kawashima A, et al. Among authors: arai y. Eur J Cancer. 2011 Jul;47(10):1521-6. doi: 10.1016/j.ejca.2011.04.001. Epub 2011 May 6. Eur J Cancer. 2011. PMID: 21550799
Importance of continuing therapy and maintaining one-month relative dose intensity in sunitinib therapy for metastatic renal cell carcinoma.
Kawashima A, Tsujimura A, Takayama H, Arai Y, Nin M, Tanigawa G, Yasunaga Y, Mukai M, Uemura M, Nakai Y, Nishimura K, Nonomura N; Osaka Renal Cell Carcinoma Clinical Study Collaboration. Kawashima A, et al. Among authors: arai y. Med Oncol. 2012 Dec;29(5):3298-305. doi: 10.1007/s12032-012-0236-6. Epub 2012 Apr 29. Med Oncol. 2012. PMID: 22544539
Impact of hyponatremia on survival of patients with metastatic renal cell carcinoma treated with molecular targeted therapy.
Kawashima A, Tsujimura A, Takayama H, Arai Y, Nin M, Tanigawa G, Uemura M, Nakai Y, Nishimura K, Nonomura N; Osaka Renal Cell Carcinoma Clinical Study Collaboration. Kawashima A, et al. Among authors: arai y. Int J Urol. 2012 Dec;19(12):1050-7. doi: 10.1111/j.1442-2042.2012.03115.x. Epub 2012 Aug 5. Int J Urol. 2012. PMID: 22860625
[Side effects of sorafenib and countermeasures].
Nakayama M, Arai Y, Nishimura K. Nakayama M, et al. Among authors: arai y. Hinyokika Kiyo. 2012 Nov;58(11):635-7. Hinyokika Kiyo. 2012. PMID: 23254792 Free article. Japanese.
[Clinical studies on renal cell carcinoma].
Tsujimoto Y, Kobayashi K, Fujita M, Arai Y, Takada T, Takada S, Honda M, Fujioka H, Matsumiya K. Tsujimoto Y, et al. Among authors: arai y. Nihon Hinyokika Gakkai Zasshi. 2010 Mar;101(3):558-64. doi: 10.5980/jpnjurol.101.558. Nihon Hinyokika Gakkai Zasshi. 2010. PMID: 20387516 Japanese.
[Hormonal chemotherapy for hormone-refractory prostate cancer].
Nishimura K, Nakai Y, Shimizu K, Tokizane T, Arai Y, Inoue H, Takaha N, Nonomura N, Okuyama A, Kamoi K, Ukimura O, Miki T, Koide T, Ichikawa Y, Nishimura K, Sugao H, Yamaguchi S, Takatera H, Uchida K, Miura H. Nishimura K, et al. Among authors: arai y. Hinyokika Kiyo. 2002 Nov;48(11):713-8. Hinyokika Kiyo. 2002. PMID: 12512147 Free article. Review. Japanese.
4,199 results